Advances in transmission-blocking vaccines against Plasmodium falciparum and Plasmodium vivax
Issued Date
2025-01-01
Resource Type
ISSN
14760584
eISSN
17448395
Scopus ID
2-s2.0-105008750540
Pubmed ID
40488614
Journal Title
Expert Review of Vaccines
Volume
24
Issue
1
Start Page
509
End Page
523
Rights Holder(s)
SCOPUS
Bibliographic Citation
Expert Review of Vaccines Vol.24 No.1 (2025) , 509-523
Suggested Citation
Tachibana M., Takashima E., Torii M., Wu Y., Sattabongkot J., Tsuboi T. Advances in transmission-blocking vaccines against Plasmodium falciparum and Plasmodium vivax. Expert Review of Vaccines Vol.24 No.1 (2025) , 509-523. 523. doi:10.1080/14760584.2025.2517720 Retrieved from: https://repository.li.mahidol.ac.th/handle/123456789/110955
Title
Advances in transmission-blocking vaccines against Plasmodium falciparum and Plasmodium vivax
Corresponding Author(s)
Other Contributor(s)
Abstract
Introduction: The World Health Organization has recommended two pre-erythrocytic malaria vaccines targeting Plasmodium falciparum. However, there is currently no vaccine available for Plasmodium vivax, the second leading cause of malaria. To eliminate malaria, transmission-blocking vaccines (TBVs) that can prevent infection of mosquitoes from humans would be helpful. Areas covered: This review summarizes the identification of targets, progress, and prospects in developing malaria TBVs. We searched PubMed for studies published up to 11 April 2025, using the terms [‘Pfs25’ OR ‘Pfs230’ OR ‘Pfs48/45’ OR ‘Pvs25’ OR ‘Pvs230’ OR ‘Pvs48/45’ OR ‘AnAPN1’] AND [‘malaria transmission-blocking vaccine’]. Expert opinion: After over 30 years of research and development, Pfs230 for P. falciparum and Pvs25 for P. vivax are the most advanced candidates for transmission-blocking vaccines.